Search results
Showing 736 to 750 of 755 results for end of life care
Aflibercept solution for injection for treating wet age‑related macular degeneration (TA294)
Evidence-based recommendations on aflibercept solution for injection (Eylea) for treating wet age-related macular degeneration in adults.
Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy (TA352)
Evidence-based recommendations on vedolizumab (Entyvio) for previously treated moderately to severely active Crohn’s disease in adults.
Insertion of an epiretinal prosthesis for retinitis pigmentosa (IPG519)
Evidence-based recommendations on insertion of an epiretinal prosthesis for retinitis pigmentosa. This involves inserting an implant into the eye that receives data from a small camera on the person's glasses and then stimulates healthy cells in the retina to see basic images.
View recommendations for IPG519Show all sections
Impella 2.5 for haemodynamic support during high-risk percutaneous coronary interventions (MIB89)
NICE has developed a medtech innovation briefing (MIB) on Impella 2.5 for haemodynamic support during high-risk percutaneous coronary interventions .
Alair bronchial thermoplasty system for adults with severe difficult to control asthma (MIB71)
NICE has developed a medtech innovation briefing (MIB) on the Alair bronchial thermoplasty system for adults with severe, difficult to control asthma
Evidence-based recommendations on edoxaban (Lixiana) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.
NICE has developed a medtech innovation briefing (MIB) on LQD Spray for treating acute and chronic wounds .
Evidence-based recommendations on ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections....
View recommendations for HTE1Show all sections
Summary of the evidence on rituximab for treating autoimmune haemolytic anaemia (AIHA) to inform local NHS planning and decision-making
NICE has developed a medtech innovation briefing (MIB) on the ThermoCool SmartTouch catheter for percutaneous radiofrequency ablation in atrial fibrillation
Interventional procedures programme manual
TactiCath Quartz catheter for percutaneous radiofrequency ablation in atrial fibrillation (MIB60)
NICE has developed a medtech innovation briefing (MIB) on the TactiCath Quartz catheter for percutaneous radiofrequency ablation in atrial fibrillation
NICE draft guidance does not recommend tucatinib for advanced breast cancer
NICE has today (26 October) published draft guidance for public consultation which does not recommend tucatinib (also called TUKYSA and made by Seagen Inc), in combination with trastuzumab and capecitabine, for some types of breast cancer that has spread.
Today (Thursday 29 November), NICE opens a public consultation on its preliminary recommendations on the NHS use of the drug, pirfenidone (known commercially as Esbriet). The draft guidance assesses whether it should be recommended for use in people who have the lung condition, idiopathic pulmonary fibrosis.
NICE recommend dapagliflozin for people with chronic kidney disease
Dapagliflozin belongs to a group of medicines called ‘sodium glucose co-transporter-2 (SGLT2) inhibitors. It is the first SGLT2 inhibitor to be recommended through NICE’s technology appraisal process for CKD.